Unknown

Dataset Information

0

Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia.


ABSTRACT: Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy originated from leukemia stem cells (LSC). Emerging evidence suggests T-cell immunoglobulin mucin-3(Tim3) as surface marker for LSC. However, the clinical significance and biology of Tim-3 in AML remain to be determined, especially those LSCs. In public AML databases as well as our data, we separated AML patients into Tim-3high and Tim-3low subsets using the X-tile software and evaluated the associations between Tim-3 and overall survival (OS) and disease-free survival (DFS). The Cancer Genome Atlas (TCGA) cohort revealed that high Tim-3 expression in leukemic cells was linked with poor prognosis (DFS: p = 0.018; OS: p = 0.041). Furthermore, multiple regression analysis shows that Tim-3 was an independent factor for the prognosis (HR = 2.26, 95% CI = 1.15-4.44, p = 0.017). Validation cohort of public gene expression omnibus (GEO) confirmed that Tim-3 was a prognostic candidate in AML. Besides, in our internal cohort, we also confirmed that over expression of Tim-3 protein in LSC/LPC made poor prognosis in AML. Additionally, we revealed that the LSC markers AKR1C3, CD34, and MMRN1 were upregulated in the Tim-3high group of TCGA. We found that the upregulated genes in the Tim-3high group were mainly enriched in immune response, cytokine binding and cell adhesion molecules, and JAK-STAT signaling pathway, by gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Collectively, we revealed that, for the first time, upregulation of Tim-3 in LSCs at the level of gene and protein expression is associated with poor prognosis and the important biological feature of Tim-3 of LSC in AML.

SUBMITTER: Wu Z 

PROVIDER: S-EPMC10134367 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia.

Wu Zhengwei Z   Ou Jiawang J   Liu Nannan N   Wang Zhixiang Z   Chen Junjie J   Cai Zihong Z   Liu Xiaoli X   Yu Xiao X   Dai Min M   Zhou Hongsheng H  

Cancer medicine 20221221 7


Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy originated from leukemia stem cells (LSC). Emerging evidence suggests T-cell immunoglobulin mucin-3(Tim3) as surface marker for LSC. However, the clinical significance and biology of Tim-3 in AML remain to be determined, especially those LSCs. In public AML databases as well as our data, we separated AML patients into Tim-3<sup>high</sup> and Tim-3<sup>low</sup> subsets using the X-tile software and evaluated the associatio  ...[more]

Similar Datasets

| S-EPMC5363646 | biostudies-literature
| S-EPMC5440863 | biostudies-other
| S-EPMC10903599 | biostudies-literature
| S-EPMC9780537 | biostudies-literature
| S-EPMC6009962 | biostudies-literature
| S-EPMC5777209 | biostudies-literature
| S-EPMC9580124 | biostudies-literature
| S-EPMC5382928 | biostudies-literature
| S-EPMC6528257 | biostudies-literature
| S-EPMC8421532 | biostudies-literature